politics
Trump Signs Executive Order to Boost Federal Research on Psychedelic Drugs
President Donald Trump signed an executive order on April 19, 2026, to promote federal medical research and clinical trials for certain psychedelic drugs. Key officials and guests, including FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr., attended the Oval Office signing.
Apr 22, 12:00 PM·1m read1 source
NB
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
President Donald Trump signed an executive order on Saturday, April 19, 2026, aiming to further federal medical research and clinical trials for certain psychedelic drugs, NBC News reported. FDA Commissioner Marty Makary was present in the Oval Office on April 19, 2026, during the signing. Health Secretary Robert F.
Kennedy Jr. was also present in the Oval Office on that date. Joe Rogan attended the event in the Oval Office as well. Americans for Ibogaine CEO W. Bryan Hubbard was in the Oval Office on April 19, 2026, for the occasion.
Former Navy SEAL Marcus Luttrell was present in the Oval Office on the same day. , Joe Rogan, Americans for Ibogaine CEO W.
The Trump administration has taken steps in the last week before April 21, 2026, to fast-track reviews of psychedelics, according to NBC News. These steps involve accelerating evaluations of psychedelics, which scientists are still assessing for safety and efficacy.
The administration's actions also include measures to widen access to some peptide injections in the same period. These developments on psychedelics and peptide injections represent recent policy moves by the administration as of April 21, 2026.
